- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Pleiad Devices Joins OmniComm's CRO Preferred ProgramTM and Chooses the TrialMasterTM Electronic Data Capture (EDC) Solution Exclusively for Clinical Trials
OmniComm Systems, Inc. (OTCBB: OMCM), a leader in integrated electronic data capture (EDC) solutions for clinical trials, today announced that after extensive evaluation of the industry's leading EDC systems, Pleiad Devices has chosen OmniComm as its preferred EDC vendor. Pleiad is an international Medical Device Contract Research Organization (CRO) with offices located in Europe and the US. The company's primary focus is providing clinical trial support services for medical device companies. As part of the partnership with OmniComm, Pleiad will take full advantage of the flexible, intuitive and robust EDC solution, TrialMaster, in an upcoming ophthalmology trial.
"Pleiad's clinical research team has years of experience in designing, organizing and managing clinical projects for medical device companies," said Stephen Brandao, Vice President of Business Development for Pleiad Devices. "Over the years, our team has had experience with most of the EDC vendors in the marketplace. TrialMaster is one of the best EDC products that we have seen and we look forward to offering our medical device customers this premier service."
The team of clinical professionals at Pleiad Devices specializes in clinical research support specifically for medical device companies. The company understands the regulatory issues in North America and Europe and provides quality clinical research services that serve regulatory, marketing and reimbursement clinical research needs internationally. Pleiad ensures compliance with all FDA and EU clinical research regulations so that all clinical data meet the regulatory standards of the major medical device markets. The clinical team offers expertise in a wide variety of areas including endovascular surgery, orthopedics, gynecology, tissue ablation, ophthalmology, combination products, drug delivery technologies and nanotechnology.
"Our CRO Preferred Program offers companies like Pleiad a true partner that will deliver the ancillary services that CROs need to be competitive in the evaluation process such as co-marketing and sales support for EDC. We offer the consummate partnership, both comprehensive company support and delivery of a first class EDC product," said Stephen Johnson, Executive Vice President of Business Development, Services and Client Services and Support. "At OmniComm, we are confident that our partnerships with CROs like Pleiad will ensure quality deliverables for the clinical research clients that we serve."
About OmniComm Systems, Inc.
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments.
OmniComm ranked in the top 150 as one of the fastest revenue growth technology companies in North America during the last 5 years. OmniComm Systems, Inc. has corporate headquarters in Ft. Lauderdale, Florida with offices in Bonn, Germany, Tula, Russia, California, Maryland, New York, North Carolina and Texas.
Safe Harbor Disclaimer
Statements about OmniComm's future expectations, including without limitation, future revenues and earnings, plans and objectives for the future operations, future agreements, future economic performance, operations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. OmniComm intends that such forward-looking statements be subject to the Safe Harbors created thereby. Since these statements involve risks and uncertainties, including but not limited to economic competitive, governmental, contractual and technological factors affecting OmniComm's operations, markets and profitability, actual results could differ materially and adversely from the expected results.
For more information, please click here
OmniComm Systems, Inc.
954-473-1254 Extension 283
Copyright © MarketwireIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Graphene under pressure August 26th, 2016
50 years after the release of the film 'Fantastic Voyage,' science upstages fiction: Science upstages fiction with nanorobotic agents designed to travel in the human body to treat cancer August 25th, 2016
Graphene under pressure August 26th, 2016
Thomas Swan and NGI announce unique partnership July 28th, 2016